Lower intensity chemo before transplant for MDS
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a less intense chemotherapy regimen to prepare patients with MDS for a stem cell transplant. It may be an option if you have intermediate or high-risk MDS and are between 14 and 70 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have been diagnosed with MDS (a bone marrow disorder) that is at intermediate or high risk according to standard scoring systems, or you need regular blood transfusions.
- You are able to perform most daily activities (ECOG score 3 or less, meaning you are up and about more than half the day).
- Your heart, liver, kidneys, and blood clotting are working well enough based on recent blood tests.
- You do not have serious heart disease, uncontrolled infections, or autoimmune diseases like lupus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 2 trial compares treatment approaches for people with higher-risk MDS or a specific type of AML before they get a stem cell transplant. The goal is to see which approach helps you get ready for transplant more safely and effectively.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
This trial tests a conditioning regimen (total marrow and lymphoid irradiation, fludarabine, and melphalan) before a donor stem cell transplant for people with high-risk myelodysplastic syndrome or acute myeloid leukemia. It aims to reduce side effects while still controlling the disease.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.